A study aimed at further elucidating the mechanism of action of sipuleucel-T (Provenge) in advanced prostate cancer provides fairly convincing evidence that the immunotherapy agent induces T-cell responses in humans, says Charles G. Drake, MD, PhD.
Among the AUA annual meeting take-home messages in basic science is that the immune co-stimulatory molecule B7-H4 is highly expressed in the luminal subtype of bladder urothelial carcinoma and is associated with poor survival.
Urologist Henry Rosevear, MD, reviews his personal highlights from AUA 2017, along with a few bumps in the road.
The FDA has approved pembrolizumab (Keytruda) for treating any solid tumors that exhibit DNA mismatch repair deficiency.
“Modern immunotherapy is active in advanced urothelial carcinoma and represents the most important advancement in the treatment of this disease in over 30 years,” says investigator Arjun V. Balar, MD.
Some patients being treated with nivolumab (Opdivo) for advanced renal cell carcinoma may still derive benefit if continued on the immunotherapy after disease progression, according to an analysis of phase III study data.
Urology Times asked members of our editorial advisory board: Has the USPSTF gone far enough with its new draft recommendation on screening for prostate cancer?
Targeted treatment with a small molecule RNA inhibitor demonstrates promising activity for promoting apoptosis of prostate cancer cells in culture, report investigators from Scripps Florida.
“The data from our study show that combination therapy [for metastatic renal cell carcinoma] may offer a much higher response rate with manageable side effects,” says study author Jianjun Gao, MD, PhD.
Administering sipuleucel-T (Provenge) before rather than after androgen deprivation therapy in men with biochemically recurrent prostate cancer appears to result in a more robust immunologic response, according to a recent study.